Compare CBOE & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBOE | RMD |
|---|---|---|
| Founded | 1973 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 33.6B |
| IPO Year | 2010 | 1996 |
| Metric | CBOE | RMD |
|---|---|---|
| Price | $362.77 | $232.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 20 |
| Target Price | ★ $355.60 | $264.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 10-30-2026 | 10-29-2026 |
| Dividend Yield | 0.98% | ★ 1.12% |
| EPS Growth | ★ 44.52 | 9.67 |
| EPS | ★ 11.08 | 2.92 |
| Revenue | $2,229,100,000.00 | ★ $2,957,013,000.00 |
| Revenue This Year | N/A | $3.12 |
| Revenue Next Year | $4.63 | $6.43 |
| P/E Ratio | ★ $31.97 | $80.92 |
| Revenue Growth | ★ 239.31 | 13.44 |
| 52 Week Low | $227.15 | $180.27 |
| 52 Week High | $371.18 | $277.67 |
| Indicator | CBOE | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 70.28 | 45.60 |
| Support Level | $273.63 | $218.45 |
| Resistance Level | $371.18 | $236.06 |
| Average True Range (ATR) | 12.86 | 7.72 |
| MACD | 2.00 | -1.91 |
| Stochastic Oscillator | 99.07 | 31.57 |
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.